
Leon Tian, Director of US Project Management, ProBio, walked through the cell line development, high-concentration formulation, and purification workflow, delivering a bispecific antibody tox batch from a single selected clone in 4 to 5 months at CDMO Live Europe 2026.Speed is always a top priority in biologic CMC development — but most of the time, speed trades against quality or regulatory confidence. What I want to show today is that this trade-off is not necessary.”ProBio’s client brought a demanding brief: a bispecific antibody project requiring a high-concentration formulation of approximately 120 mg/mL, produced from a single selected clone, with a tox batch delivered in 4 to 5 months. Tian called it a “mission impossible” scenario, then spent the session methodically explaining how ProBio’s platform addresses each part of that challenge.Read the full article.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Novartis’ Win-Win Approach to Greener Drug Development

Network Resilience: Why Dual Sourcing Alone Won’t Save You

Building a CMC Strategy That Satisfies Regulators and Attracts Investors

How Polpharma Transferred 21 Products Across Five CDMOs
Free AI-powered recaps of PharmaSource Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.